bances have one common clinical manifestation, namely, premature coronary artery disease. Patients with Down's syndrome have an additional copy of the gene that codes for cystathionine synthase, thus giving them double the amount of this enzyme. The result is that they have a much lower than normal homocysteine concentration. Patients with Down's syndrome have been noted as being remarkably free from coronary artery disease.

It has been over two decades since the publication demonstrating the original animal work of McCully and Wilson who proposed the homocysteine theory of arteriosclerosis. After being ignored for many years, homocysteine has finally re-emerged as a risk factor for the development of human atherosclerosis. Although it is "the new player in the field of coronary risk," homocysteine will become an increasingly important player that can no longer be ignored in the modern-day management of patients with coronary artery disease.

**TSUNG O CHENG**
Professor of Medicine, The George Washington University, Washington, DC 20037, USA


This letter was shown to the authors, who reply as follows:

**SIR,—**We were interested to read Pitt and colleagues' description of their patient with endomyocardial fibrosis. At the end of their discussion they mention that future management of their patient will involve assessment for cardiac transplantation. However, they do not mention endocardectomy, which we regard as the definitive treatment in suitably symptomatic patients. The operation consists of endocardial decortication, essentially a coring out of the fibrous tissue, with antroventricular valve compensation or repair. We recently had a 40 year old female Lebanese patient with endomyocardial fibrosis effecting both ventricles who underwent antroventricular endocardectomy with tricuspid valve annuloplasty. Although she had a slow recovery requiring inotropic support for five days, and was eventually discharged on the 20th postoperative day, symptomatically she was much improved.

Endocardial decortication for this disease was introduced by Dubost et al in 1973 and there are now several operative series in the literature. Most series report a hospital mortality rate of 20%, most often secondary to low cardiac output. For those who survive the operation 75% are alive after five years, and in the majority of cases there is good clinical improvement. Untreated, patients with endomyocardial fibrosis usually die within three years. Most patients in the reported series were in NYHA class III or IV and it is likely that mortality or survival will be less if patients undergo surgery at an earlier stage.

**JAMIL MAYET**
**PRAPA KANAGARATNAM**
**CHRISTOPHER LINCOLN GOLDSHAW**
Royal Brompton Hospital, Sydney Street, London SW3 6NP, United Kingdom


**Hyperesopophilic syndrome: endomyocardial fibrosis**

**SIR,—**We read with great interest the paper on endomyocardial fibrosis (EMF) by Rashwan et al. Their association of cases with hepatosplenic schistosomiasis, which was felt to be involved in the production of EMF rather than just the coincidence of two diseases, has been reported previously. We published a case report in 1973 making the suggestion of a pathogenetic relation of schistosomiasis to EMF. Another case report illustrating the association was published more recently.

**JH ANTONIO M. CIANCIO**
**HL SOARES**
Department of Internal Medicine, Faculdade de Ciências Médicas da Baía Horações, Minas Gerais—Brazil
**D MIRANDA**
**L A NUNES**
Department of Pathology, Santa Casa de Baía Horizontes, Minas Gerais—Brazil


**Deterioration in renal function with enalapril but not losartan in a patient with renal artery stenosis in a solitary kidney**

**SIR,—**Angiotensin-converting enzyme (ACE) inhibitors are widely used in the treatment of hypertension and heart failure. However, when given to patients with bilateral renal artery stenosis or unilateral stenosis in a solitary kidney, they can cause renal impairment that is usually reversible on stopping the drug. Recently, an angiotensin II (AII) receptor blocker (losartan) was introduced for the treatment of hypertension. We report a patient with severe hypertension and apparent heart failure who developed renal impairment with an ACE inhibitor but not with the AII receptor antagonist.

A 73 year old man with a previous history of severe hypertension was admitted to hospital with symptoms and signs of biventricular failure. Blood pressure was 150/90 mmHg and apical heart rate was 148 beats/min on treatment with digoxin 25 μg daily, frusemide 40 mg daily, enalapril 10 mg twice daily, nifedipine LA 30 mg daily, and warfarin. Serum creatinine was 308 μmol/l. Renal ultrasonography showed a small left kidney (8.9 cm) and a normal size right kidney. Echocardiography revealed concentric left ventricular (LV) hypertrophy, no valve lesions and good LV function.

Coronary angiography revealed an 80% diffuse disease of the left anterior descending artery, and a 50% obtuse marginal stenosis. Renal angiography performed at the same time revealed total occlusion of the left renal artery and a proximal severe stenosis of a single right renal artery (fig). Enalapril was therefore discontinued and five days later serum creatinine fell to 148 μmol/l. Subsequently, blood pressure and symptoms of apparent heart failure were difficult to control despite adequate treatment of the arterial fibrillation. The patient was then started on losartan 50 mg twice daily in addition to two frumil (co-amilorfruse 5/40)}
In our own investigations we examined the effect of delayed separation where the sample, collected into polypropylene tubes containing EDTA, with and without the addition of aprotinin, was maintained as whole blood at room temperature and at 0°C for one to three hours. Plasma ANP levels were measured by radioimmunoassay following Sep-pak plasma extraction as previously described. The results demonstrated that the addition of aprotinin made little difference to the plasma concentration of the C-terminal ANP (table).

G MCDOWELL
C SHAW
KD BUCHANAN
DP NICHOLLS
Royal Victoria Hospital,
Grosvenor Road,
Belfast, BT12 6BA, United Kingdom


NOTICES

An Introduction to Vascular Biology will be held at St Thomas’ Hospital, London, United Kingdom on 8-9 May, 1997. For further information, please contact the Secretariat, Hampton Medical Conferences, 127 High Street, Teddington, Middlesex TW11 8HH. (Tel: 0181 977 0011; fax: 0181 977 0055).

The 1997 Cardiology for Consultants weekend symposium designed for consultants and doctors training in cardiology is to be held at Exeter College, Oxford from 4-6 July, 1997. All conference costs and accommodation are covered by an educational grant from Bayer plc. A booking fee of £30 (cheque made payable to BHF) is refundable at the symposium. For an application form please telephone +0(1291) 672528.

The International Congress of Cardiac Imaging will be held at the Queen Mother Conference Centre, Edinburgh from 1–3 September, 1997. For further information, please contact Helen Wilde, 6 Napier Road, Redland, Bristol, United Kingdom. (Tel/fax: +0(117) 9739746; e-mail.m.res@bris.ac.uk) or visit <http://www.his.path.cam.ac.uk/rad/rodi/html> on the Internet.

The 70th European Atherosclerosis Society Congress will be held in Jerusalem, Israel from 6-9 September, 1998. For further information please contact Professor Yechezkel Stein, 70th EAS Congress, POB 50006, Tel Aviv 61500, Israel. (Tel: +972 3 5140014; fax: +972 3 5175674/5140077.)

Aortography showing severe proximal renal artery stenosis in a single functioning kidney.

daily, doxazosin 4 mg daily, digoxin 250 μg daily and warfarin. However, there was only mild reduction in blood pressure (183/102 mm Hg), but rather surprisingly there was no deterioration in serum creatinine (175 μmol/l). A successful renal angioplasty was undertaken six months later.

This case confirms our previous observation where, in hypertensive patients with renal impairment, unilateral stenosis in a single functioning kidney may cause apparent congestive heart failure in the absence of overt left ventricular dysfunction or valvar heart disease. The observation that renal function deteriorated with an ACE inhibitor, but not with an AR receptor antagonist, is of interest as we are unaware of any other reports.

CONSTANTINOS G MISSOURIS
DAVID E WARD
JOHN B EASTWOOD
GRAHAM A MACGREGOR
Department of Cardiology, Department of Renal Medicine, and Blood Pressure Unit, Department of Medicine, St George’s Hospital Medical School, Cranmer Terrace, London SW17 0RE, United Kingdom


Stability of plasma concentrations of N- and C-terminal atrial natriuretic peptides at room temperature

Str,-In their study of the stability of N- and C-terminal atrial natriuretic peptides (ANP) Cleland et al. compared the storage of samples at –20°C and –70°C. They found no difference between plasma C-terminal ANP concentrations when the samples were centrifuged immediately and stored at –70°C or –20°C, or if kept at room temperature as whole blood for six hours or plasma for up to 24 hours.

Dr Cleland also examined the role of aprotinin (Trasylol) in sample preservation. The addition of aprotinin to the sample made no difference to the N-terminal ANP concentration, but the effect on the C-terminal ANP concentration is not documented.

The stability of ANP in whole blood. The effect of time and aprotinin

<table>
<thead>
<tr>
<th>Whole</th>
<th>Time (hours)</th>
<th>With aprotinin</th>
<th>Without aprotinin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Room</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Room</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Room</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results are expressed at percentage of the original ANP concentration (n = 5). Recovery of ANP when processed immediately is >96%.
Deterioration in renal function with enalapril but not losartan in a patient with renal artery stenosis in a solitary kidney.


*Heart* 1997 77: 391-392
doi: 10.1136/hrt.77.4.391-b

Updated information and services can be found at:
http://heart.bmj.com/content/77/4/391.1.citation

**Email alerting service**

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/